[Form 4] Sensus Healthcare, Inc Insider Trading Activity
Michael Sardano, who serves as a director and as President and General Counsel of Sensus Healthcare, Inc. (SRTS), reported a purchase of 1,000 shares of the company's common stock on 08/13/2025 at a reported price of $3.37 per share. After the transaction, his reported direct beneficial ownership totaled 116,839 shares. The Form 4 lists the transaction code as "P" and shows the change as an acquisition.
Michael Sardano, membro del consiglio e Presidente e General Counsel di Sensus Healthcare, Inc. (SRTS), ha dichiarato l'acquisto di 1,000 azioni del capitale sociale della società in data 08/13/2025 a un prezzo indicato di $3.37 per azione. Dopo la transazione, la sua partecipazione diretta complessiva è risultata essere di 116,839 azioni. Il Modulo 4 riporta il codice dell'operazione come "P" e indica la variazione come un'acquisizione.
Michael Sardano, que se desempeña como director y como Presidente y Asesor Jurídico General de Sensus Healthcare, Inc. (SRTS), informó la compra de 1,000 acciones de las acciones ordinarias de la compañía el 08/13/2025 a un precio reportado de $3.37 por acción. Tras la operación, su participación directa beneficiaria reportada ascendió a 116,839 acciones. El Formulario 4 registra el código de la transacción como "P" y la clasifica como una adquisición.
Michael Sardano는 이사회 이사이자 Sensus Healthcare, Inc. (SRTS)의 사장 겸 법무총괄로서 회사 보통주 1,000주를 08/13/2025에 주당 $3.37에 매수했다고 신고했습니다. 거래 후 그의 보고된 직접 실질 소유는 총 116,839주였습니다. Form 4에는 거래 코드가 "P"로 기재되어 있으며 변동은 취득으로 표시되어 있습니다.
Michael Sardano, qui exerce les fonctions d'administrateur ainsi que de président et conseiller juridique principal de Sensus Healthcare, Inc. (SRTS), a déclaré l'achat de 1,000 actions des actions ordinaires de la société le 08/13/2025 à un prix déclaré de $3.37 par action. Après la transaction, sa participation directe bénéficiaire déclarée s'élevait à 116,839 actions. Le formulaire 4 indique le code de la transaction comme "P" et montre que le changement correspond à une acquisition.
Michael Sardano, der als Direktor sowie als Präsident und General Counsel von Sensus Healthcare, Inc. (SRTS) tätig ist, meldete den Kauf von 1,000 Aktien der Stammaktien des Unternehmens am 08/13/2025 zu einem gemeldeten Preis von $3.37 pro Aktie. Nach der Transaktion belief sich sein gemeldeter direkter wirtschaftlicher Besitz auf insgesamt 116,839 Aktien. Auf dem Formular 4 wird der Transaktionscode als "P" angegeben und die Änderung als Erwerb ausgewiesen.
- Insider acquisition reported: Michael Sardano acquired 1,000 shares of Sensus Healthcare common stock.
- Increased disclosed insider ownership: Reported direct beneficial ownership rose to 116,839 shares.
- None.
Insights
TL;DR: Officer purchase of 1,000 shares at $3.37 increased direct holdings to 116,839; transaction appears modest with limited market impact.
The Form 4 shows a non-derivative acquisition on 08/13/2025 where Michael Sardano purchased 1,000 common shares at $3.37, raising his direct beneficial ownership to 116,839 shares. The disclosure is straightforward and procedural; there is no additional information on plans or larger trading patterns in the filing to suggest material change in insider exposure.
TL;DR: A director and executive reported a small direct purchase; it increases disclosed insider ownership but is not a material shift.
The filing identifies Sardano as both a director and as President and General Counsel and documents a purchase recorded under transaction code "P." The report updates public records of insider holdings to 116,839 shares. The filing provides clear compliance with Section 16 reporting requirements but contains no governance actions or changes in role.
Michael Sardano, membro del consiglio e Presidente e General Counsel di Sensus Healthcare, Inc. (SRTS), ha dichiarato l'acquisto di 1,000 azioni del capitale sociale della società in data 08/13/2025 a un prezzo indicato di $3.37 per azione. Dopo la transazione, la sua partecipazione diretta complessiva è risultata essere di 116,839 azioni. Il Modulo 4 riporta il codice dell'operazione come "P" e indica la variazione come un'acquisizione.
Michael Sardano, que se desempeña como director y como Presidente y Asesor Jurídico General de Sensus Healthcare, Inc. (SRTS), informó la compra de 1,000 acciones de las acciones ordinarias de la compañía el 08/13/2025 a un precio reportado de $3.37 por acción. Tras la operación, su participación directa beneficiaria reportada ascendió a 116,839 acciones. El Formulario 4 registra el código de la transacción como "P" y la clasifica como una adquisición.
Michael Sardano는 이사회 이사이자 Sensus Healthcare, Inc. (SRTS)의 사장 겸 법무총괄로서 회사 보통주 1,000주를 08/13/2025에 주당 $3.37에 매수했다고 신고했습니다. 거래 후 그의 보고된 직접 실질 소유는 총 116,839주였습니다. Form 4에는 거래 코드가 "P"로 기재되어 있으며 변동은 취득으로 표시되어 있습니다.
Michael Sardano, qui exerce les fonctions d'administrateur ainsi que de président et conseiller juridique principal de Sensus Healthcare, Inc. (SRTS), a déclaré l'achat de 1,000 actions des actions ordinaires de la société le 08/13/2025 à un prix déclaré de $3.37 par action. Après la transaction, sa participation directe bénéficiaire déclarée s'élevait à 116,839 actions. Le formulaire 4 indique le code de la transaction comme "P" et montre que le changement correspond à une acquisition.
Michael Sardano, der als Direktor sowie als Präsident und General Counsel von Sensus Healthcare, Inc. (SRTS) tätig ist, meldete den Kauf von 1,000 Aktien der Stammaktien des Unternehmens am 08/13/2025 zu einem gemeldeten Preis von $3.37 pro Aktie. Nach der Transaktion belief sich sein gemeldeter direkter wirtschaftlicher Besitz auf insgesamt 116,839 Aktien. Auf dem Formular 4 wird der Transaktionscode als "P" angegeben und die Änderung als Erwerb ausgewiesen.